Key Highlights:
- Seven biotech stocks fell between 11.70% and 43.04% in the Friday, October 23, 2026 session.
- Aardvark Therapeutics dropped 43.04% to $2.25 after exploratory data from a terminated trial.
- Tango Therapeutics holds about $1.0 billion in cash, roughly 13.5 times Aardvark's $73.9 million (calculated).
- Phathom Pharmaceuticals grew VOQUEZNA revenue 88% but carries a $344.3 million stockholders' deficit.
- Sunshine Biopharma trades about 73% below its October offering price (calculated).
Which Biotech Stocks Fell the Most on October 23, 2026?
Aardvark Therapeutics (NASDAQ:AARD) fell 43.04% to $2.25 after exploratory data from its terminated Phase 3 HERO trial, and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) dropped 28.60% to $0.3495 with no announced catalyst. MacroGenics (NASDAQ:MGNX) lost 20.11% to $2.90 on the day of a scheduled poster, Phathom Pharmaceuticals (NASDAQ:PHAT) fell 15.55% to $5.92 and Tango Therapeutics (NASDAQ:TNGX) slid 15.11% to $23.71 as the ESMO congress opened. Sunshine Biopharma (NASDAQ:SBFM) declined 12.40% to $0.1463 weeks after an offering, and Enlivex (NASDAQ:ENLV) fell 11.70% to $0.1759 after a workforce cut and a reverse split plan.
The cash positions range from about $1.0 billion down to roughly $11,700, so the common label hides very different risks.
Aardvark Therapeutics: How Long Does Its Cash Last After the HERO Setback?
Aardvark held $73.9 million at June 30, down from $91.2 million at March 31, against a second-quarter net loss of $14.4 million, and it guides to runway into late 2027. Research spending fell to $10.5 million from $13.1 million, and the six-month net loss was $36.0 million. The FDA lifted the clinical hold on October 22, yet the HERO trial, stopped at 67 of 90 planned participants, showed only a modest effect that faded after dosing ended. Prader-Willi studies are due to resume in 2027, subject to a design meeting the company plans to request.
Lakewood-Amedex Biotherapeutics: How Thin Is the Balance Sheet Behind the Drop?
Filings show cash of about $11,700 on March 31 against a first-quarter net loss of $923,291 and an accumulated deficit of $54.3 million, with a going-concern warning. The company develops a gel for infected diabetic foot ulcers that is in Phase 2a testing, and it holds 68 issued patents. A Series C preferred financing in April raised $7.5 million gross, and a 1-for-10 reverse split followed on June 19. Short interest rose about 146.8% by mid-October, according to market estimates.
MacroGenics: Does Pro Forma Cash Exceed What Investors Pay for the Company?
Pro forma cash of $327 million exceeds a market value near $184.6 million at $2.90 by a factor of about 1.8 (calculated), and the company guides to runway through 2028. Second-quarter revenue reached $32.8 million from $6.9 million, though net income of $19.5 million included $89.2 million from discontinued operations. Its MGC026 trial had 74 patients as of July 8 and met its first-stage threshold in head and neck cancer. Research spending was $38.8 million and administrative expense $7.9 million in the quarter. No separate catalyst was announced.
Tango Therapeutics: Is ESMO Week Weighing on a Cash-Rich Cancer Developer?
Tango reported cash of $1.0 billion and a second-quarter net loss of $55.3 million, while collaboration revenue dropped to zero from $3.2 million. A pancreatic cancer combination showed a 92% response rate and 90% six-month progression-free survival in an earlier cohort. The company announced nothing new for the session. A June update had 11 of 12 patients responding, a front-line Phase 3 design is due to be finalized in the second half, and new combination data are due at the congress running through October 27. The close sits about 14.3% below an August 10 level of $27.67 (calculated).
Phathom Pharmaceuticals: Can Sales Growth Offset a Heavy Debt Load?
VOQUEZNA net revenue climbed 88% to $74.3 million in the second quarter, and net loss narrowed to $17.6 million from $75.8 million. Even so, 2026 revenue guidance was trimmed to $310 million to $325 million, a cut of about 4.5% at the midpoint (calculated). Cash was $182.5 million against liabilities of $671.3 million, with interest expense near $15.1 million a quarter. About 325,000 prescriptions were filled in the second quarter. The company has announced no catalyst for the decline.
Sunshine Biopharma: How Much Dilution Came With the October Offering?
The $6.0 million offering priced at $0.55 per unit on October 8 and closed October 9, with 10,909,082 units each carrying two Series D warrants exercisable at $0.66. That implies about 21.8 million warrants (calculated), worth up to $14.4 million if exercised in full, for a potential $20.4 million in total. The company sells 61 generic prescription drugs in Canada and has not announced a catalyst for the session. A prior offering of up to $18.0 million closed in May, and fiscal 2025 revenue was $36.3 million.
Enlivex: What Remains After a 60% Workforce Cut?
Enlivex announced a cost plan on October 19 that cuts about 60% of staff, trims management pay and winds down programs outside its Phase 2b knee osteoarthritis trial. A 1-for-16 reverse split takes effect October 27, reducing shares from 24,511,905 to about 1,531,995. At $0.1759, the split-adjusted price would be about $2.81, and equity value near $4.3 million (calculated). Topline Phase 2b data are expected by mid-2027, and no cash figure was given. An earlier Phase 2a study showed a 72% pain reduction against placebo at three months in patients aged 60 and over.
Biotech Decliners Compared: Which Balance Sheet Offers the Longest Cushion?
Dividing reported cash by each company's latest quarterly net loss (calculated), Tango Therapeutics covers about 18.1 quarters, Phathom Pharmaceuticals about 10.4 and Aardvark Therapeutics about 5.1. Lakewood-Amedex Biotherapeutics held about 1.3% of one quarter's loss in cash.
Against reference prices (calculated), Lakewood-Amedex Biotherapeutics trades about 81.2% below its September 17 level of $1.86, Sunshine Biopharma about 73.4% below its offering price and Tango Therapeutics about 14.3% below its August close. The spread between the deepest and shallowest falls is 31.34 points (calculated).
What to Watch Next: Which Dated Biotech Events Come First?
MacroGenics presents a lorigerlimab poster on October 26, and Tango Therapeutics' ESMO data run through October 27, the same day Enlivex's reverse split takes effect. Phathom Pharmaceuticals reports third-quarter results on October 29, 2026, with Phase 2 data in eosinophilic esophagitis due in the fourth quarter. MacroGenics expects MGC028 data in late 2026, while Aardvark Therapeutics, Sunshine Biopharma and Lakewood-Amedex Biotherapeutics have not announced reporting dates.
Aardvark Therapeutics fell 43.04% to $2.25 after exploratory data from its terminated Phase 3 HERO trial.
Tango Therapeutics reported about $1.0 billion at June 30, 2026, the largest balance in the group.
It reports third-quarter results on October 29, 2026.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...